 |
|
New nanoparticle vaccine is more effective but less expensive
September 17, 2007Good news for public health: Bioengineering researchers from the EPFL in Lausanne, Switzerland, have developed and patented a nanoparticle that can deliver vaccines more effectively, with fewer side effects, and at a fraction of the cost of current vaccine technologies.
Described in an article appearing online September 16 in the journal Nature Biotechnology, the vaccine delivery platform is a deceptively simple combination of nanotechnology and chemistry that represents a huge advantage over current vaccine methods. This technology may make it possible to vaccinate against diseases like hepatitis and malaria with a single injection. And at an estimated cost of only a dollar a dose, this technology represents a real breakthrough for vaccine efforts in the developing world.
A vaccination is an injection of a non-virulent form of a pathogen or molecule from a pathogen (known as an antigen), to which the immune system responds, destroying and then developing a "memory" for the pathogen. Later, when a virulent form of the pathogen comes along, this memory kicks in and the intruder is quickly eradicated. Most vaccines protect against viruses or bacteria, but vaccine techniques are also being explored as a way to kill cancer cells.
Thanks to recent advances, an immune response can be triggered with just a single protein from a virus or bacterium. Recent research has also shown that the best way to get sustained immunity is to deliver an antigen directly to specialized immune cells known as dendritic cells (DCs).
This technique is not yet used clinically because there are two difficulties to overcome in targeting the DCs: first, there are not very many of these cells in the skin or muscle, where injections are usually made, so obtaining an adequate immune response with a single injection is difficult; and second, activating the DCs requires co-delivering a "danger signal" of some sort, otherwise the immune system will just ignore it. Current approaches mimic bacterial molecules already known to the immune system, but this can cause side effects or even be toxic.
EPFL professors Jeff Hubbell and Melody Swartz and PhD student Sai Reddy have engineered nanoparticles that completely overcome these limitations. At a mere 25 nanometers, these particles are so tiny that once injected, they flow through the skin's extracellular matrix, making a beeline to the lymph nodes. Within minutes, they've reached a concentration of DCs thousands of times greater than in the skin. The immune response can then be extremely strong and effective.
In addition, the EPFL team has also engineered a special chemical coating for the nanoparticles that mimics the surface chemistry of a bacterial cell wall. The DCs don't recognize this as a specific invader, but do know that it's something foreign, and so a low-level, generic immune reaction known as "complement" is triggered. This results in a particularly potent immune response without the risk of unpleasant or toxic side effects.
"People have been exploring nanoparticles for a while," says Hubbell. "Our ideas -- to activate complement as a danger signal, and to exploit the slow interstitial flow towards the lymph nodes - are completely new. But it meant that our particles had to be much smaller than anything currently being developed. No other labs have managed to engineer so many levels of functionality into nanoparticles that are smaller than biologically occurring particles," he adds. "The beauty of it is that once we have developed the recipe, any lab can make them."
Cost and logistics are important factors, especially for use in developing countries. Unlike other nanoparticle vaccine technologies that degrade in water and thus require expensive drying and handling procedures, the EPFL team's nanoparticles won't degrade until they are in the body. They are in liquid form and don't require refrigeration, so preparation and handling costs are reduced, and they are easy to transport.
The group is collaborating with the Swiss Tropical Institute in Basel to determine the strength and duration of the immune response in the context of a nanoparticle malaria vaccine. Toxicity studies are also in the works. Swartz says that the team is also planning to use this technique to target cancer cells.
"If, as we hope, this vaccine technique can confer sustained immunity with a single injection for around a dollar a dose, without toxic side effects, it could have a real impact on public health, in the developing world as well as right here at home," says Swartz. "More study is required to achieve these goals," she adds, "but we have every reason to believe this technique could be in use within five years."
Ecole Polytechnique Fédérale de Lausanne
Thanks to recent advances, an immune response can be triggered with just a single protein from a virus or bacterium. Recent research has also shown that the best way to get sustained immunity is to deliver an antigen directly to specialized immune cells known as dendritic cells (DCs).
This technique is not yet used clinically because there are two difficulties to overcome in targeting the DCs: first, there are not very many of these cells in the skin or muscle, where injections are usually made, so obtaining an adequate immune response with a single injection is difficult; and second, activating the DCs requires co-delivering a "danger signal" of some sort, otherwise the immune system will just ignore it. Current approaches mimic bacterial molecules already known to the immune system, but this can cause side effects or even be toxic.
EPFL professors Jeff Hubbell and Melody Swartz and PhD student Sai Reddy have engineered nanoparticles that completely overcome these limitations. At a mere 25 nanometers, these particles are so tiny that once injected, they flow through the skin's extracellular matrix, making a beeline to the lymph nodes. Within minutes, they've reached a concentration of DCs thousands of times greater than in the skin. The immune response can then be extremely strong and effective.
In addition, the EPFL team has also engineered a special chemical coating for the nanoparticles that mimics the surface chemistry of a bacterial cell wall. The DCs don't recognize this as a specific invader, but do know that it's something foreign, and so a low-level, generic immune reaction known as "complement" is triggered. This results in a particularly potent immune response without the risk of unpleasant or toxic side effects.
"People have been exploring nanoparticles for a while," says Hubbell. "Our ideas -- to activate complement as a danger signal, and to exploit the slow interstitial flow towards the lymph nodes - are completely new. But it meant that our particles had to be much smaller than anything currently being developed. No other labs have managed to engineer so many levels of functionality into nanoparticles that are smaller than biologically occurring particles," he adds. "The beauty of it is that once we have developed the recipe, any lab can make them."
Cost and logistics are important factors, especially for use in developing countries. Unlike other nanoparticle vaccine technologies that degrade in water and thus require expensive drying and handling procedures, the EPFL team's nanoparticles won't degrade until they are in the body. They are in liquid form and don't require refrigeration, so preparation and handling costs are reduced, and they are easy to transport.
The group is collaborating with the Swiss Tropical Institute in Basel to determine the strength and duration of the immune response in the context of a nanoparticle malaria vaccine. Toxicity studies are also in the works. Swartz says that the team is also planning to use this technique to target cancer cells.
"If, as we hope, this vaccine technique can confer sustained immunity with a single injection for around a dollar a dose, without toxic side effects, it could have a real impact on public health, in the developing world as well as right here at home," says Swartz. "More study is required to achieve these goals," she adds, "but we have every reason to believe this technique could be in use within five years."
Ecole Polytechnique Fédérale de Lausanne
Immune Response Current Events and Immune Response News RSSResults of landmark study of HIV vaccine published in the Lancet
Results from the Step study, a test-of-concept efficacy study of a Merck & Co., Inc. HIV vaccine candidate, were published online today in two papers in The Lancet. These analyses of the Step study are being conducted, presented and published to inform the continued search for an effective HIV vaccine.
Plastic surgeons warn of malnutrition in body contouring patients
Identifying malnutrition before surgery in massive weight loss patients seeking body contouring will significantly decrease surgical complications, accelerate wound healing, improve scar quality and boost patient energy levels, according to a study in the December issue of Plastic and Reconstructive Surgery.
Could vitamin D save us from radiation?
Radiological health expert Daniel Hayes, Ph.D., of the New York City Department of Health and Mental Hygiene suggests that a form of vitamin D could be one of our body's main protections against damage from low levels of radiation.
Engineered killer T cell recognizes HIV-1's lethal molecular disguises
Researchers at the University of Pennsylvania School of Medicine and colleagues in the United Kingdom have engineered T cells able to recognize HIV-1 strains that have evaded the immune system.
T cell-based HIV vaccine candidate demonstrates positive results
The question of whether or not to continue to pursue the development of T-cell-based HIV-1 vaccines has been a source of controversy following last year's widely publicized failure of the field's most promising candidate, a vaccine developed by Merck known as V520.
New study shows that important gene controls the ability of the thymus to produce disease-fighting T-cells after an organism's birth
New research, just published by researchers from the University of Georgia, provides the first evidence that a key gene may be crucial to maintaining the production of the thymus and its disease-fighting T-cells after an animal's birth.
Mayo Clinic Researchers Find Predictive Tests and Early Treatment Delay Progression of Blood Cell Cancer
Mayo Clinic researchers say they have moved closer to their goal of providing personalized care for a common blood cell cancer.
Protein 'tubules' free avian flu virus from immune recognition
A protein found in the virulent avian influenza virus strain called H5N1 forms tiny tubules in which it "hides" the pieces of double-stranded RNA formed during viral infection, which otherwise would prompt an antiviral immune response from infected cells, said Baylor College of Medicine researchers in an online report in the journal Nature.
Proteomics Study Yields Clues As To How Tuberculosis Might Be Thwarting The Immune System
A link between the immune system and the self-cleaning system by which biological cells rid themselves of obsolete or toxic parts may one day yield new weapons in the fight against tuberculosis and other deadly infectious diseases.
Persistent bacterial infection exploits killing machinery of immune cells
A new study reveals an important and newly discovered pathway used by disease-causing bacteria to evade the host immune system and survive and grow within the very cells meant to destroy them. This discovery may lead to new treatments and vaccines for tuberculosis (TB) and certain other chronic bacterial and parasitic infections.
More Immune Response Current Events and Immune Response News Articles
 | The Immune Response: Basic and Clinical Principles by Tak W. Mak, Mary Saunders The Immune Response is a unique reference work covering the basic and clinical principles of immunology in a modern and comprehensive fashion. Written in an engaging conversational style, the book conveys the broad scope and fascinating appeal of immunology. The book is beautifully illustrated with superb figures as well as many full color plates. This extraordinary work will be an invaluable... |
 | Immune Response and the Eye (Chemical Immunology) In memory of J. Wayne Streilein, the pioneer in ocular immunology The second edition of Immune >Response and the Eye' highlights recent insights into the >dangerous compromise' between the immune system and the eye, which protects the eye against pathogens while limiting inflammation and immune-mediated injury to ocular tissues with little or no regenerative potential. It discusses the... |
 | Primer to The Immune Response by Tak W. Mak, Mary Saunders Primer to The Immune Response is an invaluable resource for college students, university undergraduates and students in medicine and other health professions who need a concise but complete and understandable introduction to immunology.This book is written in the same engaging conversational style as the published reference book The Immune Response: Basic and Clinical Principles and conveys the... |
 | Immunity: The Immune Response to Infectious and Inflammatory Disease (Primers in Biology) by Anthony DeFranco, Richard Locksley, Miranda Robertson An understanding of the immune system is central to the understanding of how the body interacts with its surroundings, and how it both protects itself and responds to infectious disease. But what processes underpin the body's response to infection? How does our immune system remember its previous encounters? And what happens when the tight regulation of the immune system fails? Immunity:... |
 | Cellular Signaling and Innate Immune Responses to RNA Virus Infections Infections with RNA viruses represent a significant cause of morbidity and mortality in vertebrates. This volume is written with the belief that a careful examination of the early host responses to these RNA virus infections, as well as of the mechanisms adopted by these viruses to evade early host antiviral responses, will provide a platform of knowledge on which we will be able to develop new... |
| The Cellular Basis of the Immune Response: An Approach to Immunobiology by Edward S. Golub | |
| Microarrays, Immune Responses, and Vaccines (Annals of the New York Academy of Sciences) This volume assesses the current impact of microarray technology on our knowledge and understanding of immunology, and on vaccine development. Questions that are addressed include the following: What microarray technological improvements remain to be achieved? What are the current biological limitations on generating new insights? In which areas should emphasis be placed in order to move ahead... | |
 | Molecular Mechanisms of Immune Responses in Insects by Paul T. Brey, Dan E. Hultmark Insects are the most numerous and diverse group of animals on earth, not only in number of individuals, but also in number of species. They inhabit virtually all terrestrial and freshwater environments, where they must protect themselves from an array of commensal, pathogenic and parasitic organisms that share the same ecological niches. Since the early 20th century, scientists have been... |
| Regulation of the Immune Response | |
| Cancer Surveys Volume 22 Molecular Mechanisms of the Immune Response by W.F. and M.J. Owen editors Bodmer |
| © 2008 BrightSurf.com |